Slan Medicinal Holdings

Slan Medicinal Holdings is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for oncology. The company specializes in targeting DNA Damage Response (DDR) pathways to treat various solid tumors, including those with specific genetic deficiencies like BRCA mutations. Its lead programs include inhibitors of DNA polymerase theta and PARP1, designed to overcome resistance to existing therapies and provide more targeted treatment options. Slan Medicinal operates primarily out of China and the United States, leveraging a robust R&D platform to advance its pipeline through global clinical trials.